Related Experiment Video

Updated: Feb 22, 2026

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

2.0K

Clinical Reasoning: A 15-month-old boy with progressive lethargy and spasticity

Rachel Zhang1, Julie Ziobro2, Jennifer Harmon1

  • 1From the Division of Infectious Disease (R.Z., B.J., A.H.), Department of Neurology (J.Z., L.T.), Pediatric Residency Program (J.H.), and Department of Ophthalmology (M.M.), Children's National Health System; Department of Ophthalmology (F.R.A.), Georgetown University Hospital; and Departments of Pediatrics (M.M., B.J., A.H.) and Ophthalmology (M.M.), George Washington University School of Medicine and Health Sciences, Washington, DC.

Neurology
|September 20, 2017
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy10:02

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy

Published on: November 3, 2016

25.7K
Event-related Potentials During Target-response Tasks to Study Cognitive Processes of Upper Limb Use in Children with Unilateral Cerebral Palsy08:26

Event-related Potentials During Target-response Tasks to Study Cognitive Processes of Upper Limb Use in Children with Unilateral Cerebral Palsy

Published on: January 11, 2016

12.7K

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K